Allogeneic HCT using peripheral blood stem cell (PBSC) grafts have better outcomes when the grafts contain large doses of invariant natural killer T (iNKT) cells, according to a single-center study of 80 consecutive patients transplanted between 2010 and 2013. In patients receiving iNKT cell doses above and below the median, GVHD-free and progression-free survival (GPFS) were 49% vs. 22%, respectively (p=0.007). In multivariate analysis, iNKT cell dose was the only factor with a significant impact on GPFS (hazard ratio=0.48; 95% CI, 0.27-0.85, p=0.01). Improved GPFS is mainly attributed to a decreased risk of relapse. The authors note that their results “may pave the way for prospective and active interventions to manipulate graft content in order to improve HCT outcome.”
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Higher Dose of Invariant Natural Killer T Cells Improves HCT Outcomes
Mar 2016